Activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in normal cells inhibits carcinogenesis, whereas constitutive activation of Nrf2 in cancer cells promotes tumor growth and chemoresistance. However, the effects of Nrf2 activation in immune cells during lung carcinogenesis are poorly defined and could either promote or inhibit cancer growth. Our studies were designed to evaluate tumor burden and identify immune cell populations in the lungs of Nrf2 knockout (KO) versus wild-type (WT) mice challenged with vinyl carbamate.
Results:
Nrf2 KO mice developed lung tumors earlier than the WT mice and exhibited more and larger tumors over time, even at late stages. T cell populations were lower in the lungs of Nrf2 KO mice, whereas tumor-promoting macrophages and myeloid-derived suppressor cells were elevated in the lungs and spleen, respectively, of Nrf2 KO mice relative to WT mice. Moreover, 34 immune response genes were significantly upregulated in tumors from Nrf2 KO mice, especially a series of cytokines (Cxcl1, Csf1, Ccl9, Cxcl12, etc.) and major histocompatibility complex antigens that promote tumor growth.
Innovation:
Our studies discovered a novel immune signature, characterized by the infiltration of tumor-promoting immune cells, elevated cytokines, and increased expression of immune response genes in the lungs and tumors of Nrf2 KO mice. A complementary profile was also found in lung cancer patients, supporting the clinical significance of our findings.
Conclusion:
Overall, our results confirmed a protective role for Nrf2 in late-stage carcinogenesis and, unexpectedly, suggest that activation of Nrf2 in immune cells may be advantageous for preventing or treating lung cancer. Antioxid. Redox Signal.
Get full access to this article
View all access options for this article.
References
1.
AharinejadS, SalamaM, PaulusP, ZinsK, BergerA, and SingerCF. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer, 20: 777–783, 2013.
2.
AlamJ, StewartD, TouchardC, BoinapallyS, ChoiAM, and CookJL. Nrf2, a Cap'n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem, 274: 26071–26078, 1999.
3.
AndersS, ReyesA, and HuberW. Detecting differential usage of exons from RNA-Seq data. Genome Res, 22: 2008–2017, 2012.
4.
AnwarAA, LiFY, LeakeDS, IshiiT, MannGE, and SiowRC. Induction of heme oxygenase 1 by moderately oxidized low-density lipoproteins in human vascular smooth muscle cells: role of mitogen-activated protein kinases and Nrf2. Free Radic Biol Med, 39: 227–236, 2005.
5.
ArranzEE, VaraJA, Gamez-PozoA, and ZamoraP. Gene signatures in breast cancer: current and future uses. Transl Oncol, 5: 398–403, 2012.
6.
BauerAK, ChoHY, Miller-DegraffL, WalkerC, HelmsK, FostelJ, YamamotoM, and KleebergerSR. Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice. PLoS One, 6: e26590, 2011.
7.
BeuryDW, CarterKA, NelsonC, SinhaP, HansonE, NyandjoM, FitzgeraldPJ, MajeedA, WaliN, and Ostrand-RosenbergS. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J Immunol, 196: 3470–3478, 2016.
8.
BruneB, DehneN, GrossmannN, JungM, NamgaladzeD, SchmidT, von KnethenA, and WeigertA. Redox control of inflammation in macrophages. Antioxid Redox Signal, 19: 595–637, 2013.
9.
BryanHK, OlayanjuA, GoldringCE, and ParkBK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol, 85: 705–717, 2013.
10.
CampbellJD, AlexandrovA, KimJ, WalaJ, BergerAH, PedamalluCS, ShuklaSA, GuoG, BrooksAN, MurrayBA, ImielinskiM, HuX, LingS, AkbaniR, RosenbergM, CibulskisC, RamachandranA, CollissonEA, KwiatkowskiDJ, LawrenceMS, WeinsteinJN, VerhaakRG, WuCJ, HammermanPS, CherniackAD, GetzG, Cancer Genome Atlas Research Network, ArtyomovMN, SchreiberR, GovindanR, and MeyersonM. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet, 48: 607–616, 2016.
11.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489: 519–525, 2012.
12.
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511: 543–550, 2014.
13.
CaseySC, AmedeiA, AquilanoK, AzmiAS, BenenciaF, BhaktaD, BilslandAE, BoosaniCS, ChenS, CirioloMR, CrawfordS, FujiiH, GeorgakilasAG, GuhaG, HalickaD, HelferichWG, HenebergP, HonokiK, KeithWN, KerkarSP, MohammedSI, NiccolaiE, NowsheenS, Vasantha RupasingheHP, SamadiA, SinghN, TalibWH, VenkateswaranV, WhelanRL, YangX, and FelsherDW. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol, 35(Suppl): S199–S223, 2015.
14.
CeramiE, GaoJ, DogrusozU, GrossBE, SumerSO, AksoyBA, JacobsenA, ByrneCJ, HeuerML, LarssonE, AntipinY, RevaB, GoldbergAP, SanderC, and SchultzN. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2: 401–404, 2012.
15.
ChanK, LuR, ChangJC, and KanYW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A, 93: 13943–13948, 1996.
16.
ChangJT and NevinsJR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics, 22: 2926–2933, 2006.
17.
CullinanSB and DiehlJA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem, 279: 20108–20117, 2004.
18.
Del PreteA, AllavenaP, SantoroG, FumaruloR, CorsiMM, and MantovaniA. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb), 21: 264–275, 2011.
19.
DingJ, GuoC, HuP, ChenJ, LiuQ, WuX, CaoY, and WuJ. CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol, 49: 2064–2074, 2016.
20.
DranoffG. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4: 11–22, 2004.
21.
Ganan-GomezI, WeiY, YangH, Boyano-AdanezMC, and Garcia-ManeroG. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med, 65: 750–764, 2013.
22.
GaoJ, AksoyBA, DogrusozU, DresdnerG, GrossB, SumerSO, SunY, JacobsenA, SinhaR, LarssonE, CeramiE, SanderC, and SchultzN. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6: pl1, 2013.
23.
GuibertN, IlieM, LongE, HofmanV, BouhlelL, BrestP, MograbiB, MarquetteCH, DidierA, MazieresJ, and HofmanP. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives. Curr Mol Med, 15: 418–432, 2015.
24.
GuoQ, GaoBL, ZhangXJ, LiuGC, XuF, FanQY, ZhangSJ, YangB, and WuXH. CXCL12-CXCR4 axis promotes proliferation, migration, invasion, and metastasis of ovarian cancer. Oncol Res, 22: 247–258, 2014.
25.
GuoY, YuS, ZhangC, and KongAN. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic Biol Med, 88: 337–349, 2015.
26.
HayesJD, McMahonM, ChowdhryS, and Dinkova-KostovaAT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal, 13: 1713–1748, 2010.
HernandezLG and ForkertPG. Inhibition of vinyl carbamate-induced lung tumors and Kras2 mutations by the garlic derivative diallyl sulfone. Mutat Res, 662: 16–21, 2009.
29.
HuR, SawCL, YuR, and KongAN. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal, 13: 1679–1698, 2010.
30.
HungJY, HornD, WoodruffK, PrihodaT, LeSauxC, PetersJ, TioF, and Abboud-WernerSL. Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest, 94: 371–381, 2014.
31.
IidaK, ItohK, KumagaiY, OyasuR, HattoriK, KawaiK, ShimazuiT, AkazaH, and YamamotoM. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res, 64: 6424–6431, 2004.
32.
IrikiT, OhnishiK, FujiwaraY, HorladH, SaitoY, PanC, IkedaK, MoriT, SuzukiM, IchiyasuH, KohrogiH, TakeyaM, and KomoharaY. The cell–cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer, 106: 22–32, 2017.
33.
ItohK, ChibaT, TakahashiS, IshiiT, IgarashiK, KatohY, OyakeT, HayashiN, SatohK, HatayamaI, YamamotoM, and NabeshimaY. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun, 236: 313–322, 1997.
34.
ItohK, IshiiT, WakabayashiN, and YamamotoM. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res, 31: 319–324, 1999.
35.
JacksonEL, WillisN, MercerK, BronsonRT, CrowleyD, MontoyaR, JacksT, and TuvesonDA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev, 15: 3243–3248, 2001.
36.
KamphorstAO, PillaiRN, YangS, NastiTH, AkondyRS, WielandA, SicaGL, YuK, KoenigL, PatelNT, BeheraM, WuH, McCauslandM, ChenZ, ZhangC, KhuriFR, OwonikokoTK, AhmedR, and RamalingamSS. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 114: 4993–4998, 2017.
37.
KhorTO, HuangMT, PrawanA, LiuY, HaoX, YuS, CheungWK, ChanJY, ReddyBS, YangCS, and KongAN. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila), 1: 187–191, 2008.
38.
KimD, PerteaG, TrapnellC, PimentelH, KelleyR, and SalzbergSL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol, 14: R36, 2013.
KovacS, AngelovaPR, HolmstromKM, ZhangY, Dinkova-KostovaAT, and AbramovAY. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta, 1850: 794–801, 2015.
41.
KunerR. Lung cancer gene signatures and clinical perspectives. Microarrays (Basel), 2: 318–339, 2013.
42.
LealAS, WilliamsCR, RoyceDB, PioliPA, SpornMB, and LibyKT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett, 394: 76–87, 2017.
43.
LeeJM, LiJ, JohnsonDA, SteinTD, KraftAD, CalkinsMJ, JakelRJ, and JohnsonJA. Nrf2, a multi-organ protector?. FASEB J, 19: 1061–1066, 2005.
44.
LibyK, BlackCC, RoyceDB, WilliamsCR, RisingsongR, YoreMM, LiuX, HondaT, GribbleGW, LamphWW, SpornTA, DmitrovskyE, and SpornMB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther, 7: 1251–1257, 2008.
45.
LibyK, RoyceDB, RisingsongR, WilliamsCR, WoodMD, ChandraratnaRA, and SpornMB. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res, 13: 6237–6243, 2007.
46.
LibyK, RoyceDB, WilliamsCR, RisingsongR, YoreMM, HondaT, GribbleGW, DmitrovskyE, SpornTA, and SpornMB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res, 67: 2414–2419, 2007.
47.
LibyKT and SpornMB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev, 64: 972–1003, 2012.
48.
LivakKJ and SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25: 402–408, 2001.
49.
MelkamuT, QianX, UpadhyayaP, O'SullivanMG, and KassieF. Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer. Vet Pathol, 50: 895–902, 2013.
50.
MenegonS, ColumbanoA, and GiordanoS. The dual roles of NRF2 in cancer. Trends Mol Med, 22: 578–593, 2016.
51.
MiH, MuruganujanA, CasagrandeJT, and ThomasPD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc, 8: 1551–1566, 2013.
52.
MiyakeM, HoriS, MorizawaY, TatsumiY, NakaiY, AnaiS, TorimotoK, AokiK, TanakaN, ShimadaK, KonishiN, ToritsukaM, KishimotoT, RosserCJ, and FujimotoK. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia, 18: 636–646, 2016.
53.
MortazaviA, WilliamsBA, McCueK, SchaefferL, and WoldB. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods, 5: 621–628, 2008.
54.
NgoHKC, KimDH, ChaYN HK, and SurhYJ. Nrf2 mutagenic activation drives hepatocarcinogenesis. Cancer Res, 77: 4797–4808, 2017.
55.
OhtsuboT, KamadaS, MikamiT, MurakamiH, and TsujimotoY. Identification of NRF2, a member of the NF-E2 family of transcription factors, as a substrate for caspase-3(-like) proteases. Cell Death Differ, 6: 865–872, 1999.
56.
OrtizML, LuL, RamachandranI, and GabrilovichDI. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res, 2: 50–58, 2014.
57.
PalazonA, GoldrathAW, NizetV, and JohnsonRS. HIF transcription factors, inflammation, and immunity. Immunity, 41: 518–528, 2014.
58.
PantanoC, ReynaertNL, van der VlietA, and Janssen-HeiningerYM. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal, 8: 1791–1806, 2006.
59.
PoczobuttJM, DeS, YadavVK, NguyenTT, LiH, SippelTR, Weiser-EvansMC, and NemenoffRA. Expression profiling of macrophages reveals multiple populations with distinct biological roles in an immunocompetent orthotopic model of lung cancer. J Immunol, 196: 2847–2859, 2016.
60.
Prado-GarciaH, Romero-GarciaS, Aguilar-CazaresD, Meneses-FloresM, and Lopez-GonzalezJS. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol, 2012: 741741, 2012.
61.
QuP, YanC, and DuH. Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood, 117: 4476–4489, 2011.
62.
Ramos-GomezM, KwakMK, DolanPM, ItohK, YamamotoM, TalalayP, and KenslerTW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A, 98: 3410–3415, 2001.
63.
RobertsPJ and StinchcombeTE. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol, 31: 1112–1121, 2013.
64.
RushmoreTH and KongAN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab, 3: 481–490, 2002.
65.
SatohH, MoriguchiT, SaigusaD, BairdL, YuL, RokutanH, IgarashiK, EbinaM, ShibataT, and YamamotoM. NRF2 intensifies host defense systems to prevent lung carcinogenesis, but after tumor initiation accelerates malignant cell growth. Cancer Res, 76: 3088–3096, 2016.
66.
SatohH, MoriguchiT, TaguchiK, TakaiJ, MaherJM, SuzukiT, WinnardPTJr., RamanV, EbinaM, NukiwaT, and YamamotoM. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis, 31: 1833–1843, 2010.
67.
SatohH, MoriguchiT, TakaiJ, EbinaM, and YamamotoM. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res, 73: 4158–4168, 2013.
68.
SheridanC and DownwardJ. Overview of KRAS-driven genetically engineered mouse models of non-small cell lung cancer. Curr Protoc Pharmacol, 70: 14.35.1–14.35.16, 2015.
69.
SohailA, SunQ, ZhaoH, BernardoMM, ChoJA, and FridmanR. MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev, 27: 289–302, 2008.
70.
SparaneoA, FabrizioFP, and MuscarellaLA. Nrf2 and Notch signaling in lung cancer: near the crossroad. Oxid Med Cell Longev, 2016: 1–17, 2016.
71.
SpornMB and LibyKT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer, 12: 564–571, 2012.
72.
StathopoulosGT, SherrillTP, ChengDS, ScogginsRM, HanW, PolosukhinVV, ConnellyL, YullFE, FingletonB, and BlackwellTS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A, 104: 18514–18519, 2007.
73.
ToC, RingelbergCS, RoyceDB, WilliamsCR, RisingsongR, SpornMB, and LibyKT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis, 36: 769–781, 2015.
74.
WangD, SunH, WeiJ, CenB, and DuBoisRN. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res, 77: 3655–3665, 2017.
75.
WangR, ZhangJ, ChenS, LuM, LuoX, YaoS, LiuS, QinY, and ChenH. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer, 74: 188–196, 2011.
76.
WangXJ, SunZ, VilleneuveNF, ZhangS, ZhaoF, LiY, ChenW, YiX, ZhengW, WondrakGT, WongPK, and ZhangDD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 29: 1235–1243, 2008.
77.
WangZ, SunJ, FengY, TianX, WangB, and ZhouY. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. Tumour Biol, 37: 8515–8528, 2016.
78.
XieS, ZengW, FanG, HuangJ, KangG, GengQ, ChengB, WangW, and DongP. Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression. Oncol Lett, 7: 941–947, 2014.
79.
XuC, HuangMT, ShenG, YuanX, LinW, KhorTO, ConneyAH, and KongAN. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res, 66: 8293–8296, 2006.
80.
XuC, LiCY, and KongAN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res, 28: 249–268, 2005.
81.
YanHH, JiangJ, PangY, AchyutBR, LizardoM, LiangX, HunterK, KhannaC, HollanderC, and YangL. CCL9 induced by TGFbeta signaling in myeloid cells enhances tumor cell survival in the premetastatic organ. Cancer Res, 75: 5283–5298, 2015.
82.
YangDL, XinMM, WangJS, XuHY, HuoQ, TangZR, and WangHF. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer. Genet Mol Res, 14: 17699–17707, 2015.
83.
YouM, CandrianU, MaronpotRR, StonerGD, and AndersonMW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci U S A, 86: 3070–3074, 1989.
84.
YuanM, ZhuH, XuJ, ZhengY, CaoX, and LiuQ. Tumor-derived CXCL1 promotes lung cancer growth via recruitment of tumor-associated neutrophils. J Immunol Res, 2016: 1–11, 2016.
85.
YuanX, HuangH, HuangY, WangJ, YanJ, DingL, ZhangC, and ZhangL. Nuclear factor E2-related factor 2 knockdown enhances glucose uptake and alters glucose metabolism in AML12 hepatocytes. Exp Biol Med (Maywood), 242: 930–938, 2017.
86.
ZanettiM and TappingCD. T cells for cancer immunotherapy: the choice of personalized genomics. J Immunol, 194: 2049–2056, 2015.
87.
ZaynagetdinovR, SherrillTP, PolosukhinVV, HanW, AusbornJA, McLoedAG, McMahonFB, GleavesLA, DegryseAL, StathopoulosGT, YullFE, and BlackwellTS. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol, 187: 5703–5711, 2011.
88.
ZhangL, WangH, FanY, GaoY, LiX, HuZ, DingK, WangY, and WangX. Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways. Sci Rep, 7: 46763, 2017.
89.
ZhuY, KnolhoffBL, MeyerMA, NyweningTM, WestBL, LuoJ, Wang-GillamA, GoedegebuureSP, LinehanDC, and DeNardoDG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res, 74: 5057–5069, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
